The PACSIN2 Knockout Raji Polyclonal Cells represent a genetically engineered, CRISPR/Cas9-mediated polyclonal knockout cell population specifically designed to disrupt the expression of the PACSIN2 gene. This loss-of-function model provides a valuable tool for investigating PACSIN2-dependent cellular processes within a human B-lymphocyte background. The edited pool retains a heterogeneous knockout profile, enabling the study of gene function at the population level without single-cell clonal expansion, which is advantageous for preserving biological variability and reducing clonal artifacts.
The host cell line, Raji, is derived from an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma, a malignancy of B-cell origin. Raji cells maintain key characteristics of mature B lymphocytes, including surface immunoglobulin expression and the capacity for robust endocytic trafficking. As part of the adaptive immune system, these cells are widely employed to model B-cell receptor (BCR) signaling, antibody production, and lymphomagenesis. Their rapid proliferation and well-characterized signaling networks make them an ideal chassis for knockout studies targeting components of membrane dynamics.
PACSIN2 (protein kinase C and casein kinase substrate in neurons 2) belongs to the F-BAR domain family and functions as a critical regulator of membrane curvature and actin cytoskeleton remodeling. Through its F-BAR domain, PACSIN2 induces membrane invagination and directly recruits N-WASP, leading to activation of the Arp2/3 complex and subsequent actin polymerization. This mechanism is essential for endocytic vesicle formation and scission. PACSIN2 activity is modulated by phosphorylation via protein kinase C and casein kinase 2, as well as by interactions with small GTPases such as Cdc42 and Rac, and downstream effectors including Dynamin-2 and Cortactin. The protein also associates with EHD proteins and Synaptojanin, linking it to both clathrin-mediated and clathrin-independent endocytic pathways.
In Raji B cells, PACSIN2 is integral to the coordination of membrane trafficking events that underpin BCR internalization and signal transduction. Disruption of PACSIN2 expression is anticipated to impair ligand-induced endocytosis of surface receptors, alter actin dynamics at the plasma membrane, and potentially modulate downstream signaling cascades such as those mediated by receptor tyrosine kinases. The knockout model may reveal altered sensitivity to extracellular stimuli and changes in cellular migration, proliferation, or apoptosis, providing a platform to dissect PACSIN2??s role in the pathophysiology of B-cell lymphomas.
This polyclonal knockout product is suited for a range of functional assays, including transferrin uptake studies to monitor endocytic activity, Western blotting and immunofluorescence to assess PACSIN2 expression and actin organization, and flow cytometry to quantify surface markers like CD19. Migration and apoptosis assays can further evaluate the consequences of PACSIN2 loss on cell behavior. Applications extend to drug uptake mechanism studies and screening for compounds that exploit defective endocytosis in lymphoma cells. For additional technical support, please contact Ascent Research.
